Retatrutide TRIUMPH-1: the phase-3 numbers, and the asterisk
This is general educational information, not medical advice and not a recommendation to obtain or use anything. Retatrutide is investigational and not approved. The figures below are results a company reported from its own trial, not a promise of any outcome and not dosing guidance.
The short version: on 21 May 2026 Eli Lilly announced topline results from TRIUMPH-1, its first phase-3 obesity trial of retatrutide. The headline was an average 28.3% body-weight reduction on the top 12 mg dose over 80 weeks, and 45.3% of participants lost at least 30% of their weight, a range that used to belong to bariatric surgery. The numbers are real and large. The asterisk: retatrutide is still not approved, this is a company press release rather than the full peer-reviewed dataset, and anything sold under that name today is unapproved grey-market product.
The numbers Lilly reported
TRIUMPH-1 enrolled 2,339 adults with obesity, or overweight with a weight-related condition, and tested three doses of the once-weekly injection over 80 weeks.
| Metric (topline) | Result |
|---|---|
| Average weight loss, 12 mg, 80 weeks | ~28.3% (about 70 lb) |
| Participants losing ≥30% of body weight | 45.3% |
| Extension in higher-BMI group, 104 weeks | up to ~30.3% (about 85 lb) |
| Trial size | 2,339 adults |
Retatrutide is a triple agonist: one molecule that acts on the GIP, GLP-1 and glucagon receptors at once. That third target, glucagon, is what people argue makes it hit harder than the GLP-1 and GLP-1/GIP drugs that came before. On these topline figures, it is the most effective obesity drug to report phase-3 data so far.
The asterisk nobody puts in the headline
Three things temper the excitement, and they are the reason we are covering it soberly.
First, it is not approved. Topline phase-3 data is a milestone on the way to a filing, not a finish line. Lilly still has to submit its application and the FDA still has to review it, which realistically lands later. Until then there is no legal, prescribed retatrutide for weight loss.
Second, "topline" is not the full dataset. A press release gives you the best-framed headline numbers. The complete results, safety detail, and the always-important dropout and adverse-event breakdown come later, at a medical congress and in a journal. Treat the 28.3% as promising and provisional, not settled.
Third, and most practically: everything circulating right now is grey market. Because the real drug is not approved, what is sold online as "retatrutide" is unregulated research-grade material of unknown identity and purity. The trial figures were produced with a known compound, dosed and monitored in a clinical setting. They tell you nothing about the vial someone is selling on a forum.
The parts the numbers do not cover
Efficacy is only half a drug. The known trade-offs from this class apply here too. The side effects are mostly gastrointestinal, nausea, vomiting, diarrhoea, constipation, dose-dependent and worst while the dose is being escalated. And rapid weight loss on any of these drugs costs lean mass, not just fat; a meaningful share of the weight lost can be muscle, which is why protein and resistance training keep coming up. We went deep on that muscle-loss point, and on the difference between phase-2 and phase-3 data, in our retatrutide liver-damage fact-check.
What comes next
TRIUMPH-1 is the first readout of a larger program. Lilly has said more will follow later in 2026: TRIUMPH-2 in people with type 2 diabetes, and TRIUMPH-3 in people with established cardiovascular disease. Those matter, because diabetes and heart-outcome data are what turn a weight-loss number into a broader case. Full TRIUMPH-1 data at a congress will also let independent researchers pick over the safety and durability rather than take a press release at face value.
Bottom line
28.3% is a genuinely big number and retatrutide looks like the strongest incretin drug yet on the data available. It is also unapproved, reported so far only as topline, and impossible to obtain in a regulated form today. Reading the result and reading a purchase page are two very different activities. For the doses as reported in the published literature, see our retatrutide reference; to understand the drug class from scratch, start with what peptides are.
Sources
- Eli Lilly (investor release), 21 May 2026, Retatrutide delivered powerful weight loss in pivotal phase-3 obesity trial
- AJMC, Retatrutide achieves up to 30.3% average weight loss in phase-3 TRIUMPH-1
- BioPharma Dive, Lilly's triple-acting obesity drug hits goal in phase-3 trial
Take myPeptides with you
Track doses, plans and progress on your phone — end-to-end encrypted.
This article is for informational purposes only and does not replace medical advice. myPeptides gives no dosing recommendations.